Please assess the completion status of the following clinical trial:

Trial Title: Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be willing and able to give informed consent to participate in the study~* Has admitted to a hospital and has a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test by standard reverse transcription-polymerase chain reaction (RT-PCR) assay or equivalent test~* Has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19 on Day 1 such as the presence of fever (greater than or equal to (\>=)38.0 degree Celsius \[\>=100.4 degree fahrenheit\] by any route), feeling hot, feeling sweaty, headache, malaise, fatigue, muscle pain, diarrhea, nausea, vomiting, cough, sore throat, or shortness of breath upon exertion and/or at rest, or respiratory distress~* Has the presence of moderate to severe clinical signs indicative of moderate or severe illness with COVID-19 on Day 1. A. Moderate: (1) Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate \>=20 breaths per minute, SpO2 \>93% on room air at sea level, heart rate \>=90 beats per minute. (2) No clinical signs indicative of severe or critical COVID-19. B. Severe: (1) Clinical signs suggestive of severe systemic illness with COVID-19, such as respiratory rate \>=30 breaths per minute, heart rate \>=125 beats per minute, SpO2 less than or equal to (\<=) 93% on room air at sea level or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) less than (\<)300, heart rate \>=125 beats per minute. (2) No criteria met for critical COVID-19~* Has either normal renal function or mild or moderate renal impairment: estimated creatinine clearance \>30 milliliters per minute (mL/min) on Day 1~* Able to swallow the study drug (tablets)~* Men whose sexual partners are women of childbearing potential (WOCBP) must agree to comply with one of the following contraception requirements from the time of first dose of study medication (Day 1) until at least 30 days after the last dose of study medication: (a) Vasectomy with documentation of azoospermia. (b) Sexual abstinence. (c) Male condom plus partner use of one of the contraceptive~* WOCBP must agree to comply with one of the following contraception requirements from the time of first dose of study medication (Day 1) until at least 30 days after the last dose of study medication: (a) Sexual abstinence (b) Use of one of the contraceptive options (c) Vasectomy of male partner with documentation of azoospermia~Exclusion Criteria:~* The participant, in the opinion of the investigator, is not likely to survive for \>=48 hours beyond Day 1~* Has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1~* Has a documented current liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones) at screening or on Day 1~* Has a Child Pugh score \>= C~* Has a documented medical history of infection with human immunodeficiency virus or hepatitis A, B, or C at screening or on Day 1~* Has a documented active infection with tuberculosis at screening or on Day 1~* Has clinically significant ECG abnormalities at screening or on Day 1~* Requires dialysis or is on any renal replacement therapies at screening or on Day 1~* A female participant who is pregnant or planning to become pregnant during the study, breastfeeding, or has a positive pregnancy test at screening~* Receiving alpha-blockers, combined alpha/beta blockers, antihistamines, or any drugs that will affect the levels of cytokines released due to immune stress~* Has received any immunoglobulins within 6 months of screening or planned administration of any immunoglobulins during the screening and/or treatment periods~* Has a known history of drug abuse within 6 months of study start that would interfere with the participant's participation in the study~* Has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, would contraindicate their participation~* Has participated in and/or plan to participate in another clinical study~* Will be transferred to another hospital which is not a study site within 72 hours~* Cannot read and speak either English or Spanish~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: FSD201 600 mg (Type: EXPERIMENTAL): Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
- Arm B: FSD201 1200 mg (Type: EXPERIMENTAL): Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
- Arm C: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues